【摘要】 目的 :探讨CD44V6及C erbB 2表达与非小细胞肺癌临床病理特征之间的关系。方法 :采用S P免疫组化法检测 132例非小细胞肺癌、6 6例淋巴结转移癌、95例癌旁肺组织和 2 0例正常肺组织CD44V6和C erbB 2表达的情况。结果 :非小细胞肺癌CD44V6阳性表达率为 48 4 8%,明显高于癌旁肺组织 16 84%和正常肺组织 2 0 0 0 %的阳性有效率。CD44V6阳性表达与淋巴结转移状况、TNM分期、肿瘤大小和组织学类型有显著相关性。非小细胞肺癌淋巴结转移组、TNMⅢ期患者、直径>3cm的肿瘤和鳞癌CD44V6阳性表达率分别明显高于无淋巴结转移组、TNMⅠ、Ⅱ期患者、直径≤ 3cm的肿瘤和腺癌。淋巴结转移癌CD44V6阳性表达率明显高于肺原发癌。CD44V6阳性表达与患者的性别、年龄和组织学分级无显著相关性。非小细胞肺癌C erbB 2阳性表达率为 6 1 36 %,明显高于癌旁肺组织 18 95 %和正常肺组织 10 0 0 %的阳性表达率。C erbB 2阳性表达与临床病理特征无显著相关性。结论 :CD44V6阳性表达预示非小细胞肺癌具有较强的侵袭和转移能力 ,CD44V6可作为一项预测非小细胞肺癌转移潜能及判断预后的生物学指标。C erbB 2作为判断非小细胞肺癌预后的指标不理想更多还原

【Abstract】 Objective:To investigate the relationship between CD44V6 and C-erbB-2 expression and clinicpathologic characteristics in non-small cell lung carcinomas(NSCLC).Methods:CD44V6 and C-erbB-2 protein was detected by S-P immunohistochemical method in 132 cases of NSCLC, 66 cases of metastatic lymph nodes, 95 cases of paracancer lung tissue and 20 cases of normal lung tissue.Results:CD44V6 positive expression of NSCLC was 48.48%, significantly higher than that of paracancer lung tissue(16.84%) and normal lung tissue(20.00%). CD44V6 positive expression was significant correlation with lymph nodes status, TNM stage, tumor size and histological type, but was not significant correlation with the patients sex, age, and histological grade. CD44V6 positive expression in NSCLC with lymph node metastasis, TNM stage Ⅲ,tumor >3cm diameter and squamous cell carcinomas was significantly higher than that without lymph node metastasis, TNM stage Ⅰ,Ⅱ, tumor ≤3cm diameter and adenocarcinomas. CD44V6 positive expression of metastatic lymph nodes was significantly higher than that of primary lung carcinomas. C-erbB-2 positive expression of NSCLC was 61.36%, significantly higher than that of paracancer lung tissue (18.95%) and normal lung tissue (10.00%).C-erbB-2 positive expression was not significant correlation with clinicopathologic characteristics.Conclusion:CD44V6 positive expression indicated that NSCLC has stronger invasion and metastasis potential. CD44V6 is a useful marker of predicting the metastatic potential and the prognosis of NSCLC. C-erbB-2 is not an useful marker for predicting the prognosis of NSCLC.更多还原